Low-intensity Focused Ultrasound Pulsation (LIFUP) for Treatment of Temporal Lobe Epilepsy
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
We intend to use focused ultrasound to stimulate or suppress brain activity in patients with epilepsy. We hypothesize that focused ultrasound is capable of brain stimulation or suppression visible with functional MRI, and will not cause tissue damage.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 60 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Subjects with clinical evidence from their diagnostic evaluations of unilateral hippocampal dysfunction and epileptogenicity.
Subjects with seizures that have been refractory to treatment with at least three currently marketed antiepileptic drugs.
Subjects with epilepsy who would clearly benefit from surgical intervention.
Subjects who have been offered a non-dominant anterior-mesial temporal lobe resection as treatment for medication refractory epilepsy.
Subjects with a cognitive or psychiatric disorder that limits the ability to give informed consent or are unable to cooperate with the testing.
Subjects with dementia, delirium and psychotic symptoms. - Subjects with ferromagnetic materials in the head.
Subjects with severe cardiac disease, increased intracranial pressure, or a TENS unit.
Subjects who exhibit primary generalized seizures or pseudoseizures.
Subjects who have seizures secondary to drugs, alcohol, metabolic illness or progressive degenerative disease.
Subjects who have experienced status epilepticus during the 3-week baseline period prior to the operation.